Benchmark Maintains Buy on Halozyme Therapeutics, Raises Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman maintains a Buy rating on Halozyme Therapeutics (NASDAQ:HALO) and raises the price target from $50 to $60.
June 25, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Robert Wasserman maintains a Buy rating on Halozyme Therapeutics and raises the price target from $50 to $60.
The raised price target and maintained Buy rating from a reputable analyst are positive signals for investors, likely leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100